Home
Clinical Trials
NCT04404283

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

238 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-20

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone.

Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diffuse Large B-cell Lymphoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Seattle Genetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Arm

Placebo + lenalidomide + rituximab

Group Type ACTIVE_COMPARATOR

Rituximab

Intervention Type DRUG

375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.

Lenalidomide

Intervention Type DRUG

20 mg given by mouth (orally) daily

Placebo

Intervention Type OTHER

Administered via intravenous infusion every 3 weeks

Experimental Arm

Brentuximab vedotin + lenalidomide + rituximab

Group Type EXPERIMENTAL

Brentuximab vedotin

Intervention Type DRUG

1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks

Rituximab

Intervention Type DRUG

375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.

Lenalidomide

Intervention Type DRUG

20 mg given by mouth (orally) daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Brentuximab vedotin

1.2 mg/kg administered into the vein (IV; intravenously) infusion every 3 weeks

Intervention Type DRUG

Rituximab

375 mg/m\^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg injected under the skin (subcutaneous) permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.

Intervention Type DRUG

Lenalidomide

20 mg given by mouth (orally) daily

Intervention Type DRUG

Placebo

Administered via intravenous infusion every 3 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with relapsed or refractory diffuse and transformed large B-cell lymphoma (R/R DLBCL). DLBCL and cell of origin (GCB versus non-GCB) will be histologically determined by local pathology assessment for the purposes of study eligibility and stratification.
* Participants must have R/R disease following 2 or more lines of prior systemic therapy.

* For participants with transformed DLBCL, at least the last systemic therapy used must have been for DLBCL
* Participants must be HSCT or CAR-T ineligible according to the investigator and must meet at least one of the following criteria:

1. One or more co-morbidities, including cardiac, pulmonary, renal or hepatic dysfunction that in the opinion of the Investigator make the participant medically unfit to received HSCT or CAR-T therapy
2. Active disease following induction and salvage chemotherapy
3. Inadequate stem cell mobilization (for HSCT)
4. Relapse following prior HSCT or CAR-T
5. Unable to receive CAR-T therapy due to financial, geographic, insurance, or manufacturing issues
* Participants must have tumor tissue submitted to the central pathology lab. The tumor tissue submitted should be from the most recent biopsy that contains DLBCL.
* An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
* Participants must have fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and bidimensional measurable disease of at least 1.5 cm by computed tomography (CT), as assessed by the site radiologist within 28 days of Day 1.

Exclusion Criteria

* History of another malignancy within 2 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy
* History of progressive multifocal leukoencephalopathy (PML)
* Active cerebral/meningeal disease related to the underlying malignancy. Participants with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior CNS disease has been effectively treated and without progression for at least 3 months.
* Any uncontrolled Grade 3 or higher (per NCI CTCAE version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted
* Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 3 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment
* Previous treatment with brentuximab vedotin or lenalidomide.

* Previous treatment with other vedotin-based ADCs is permitted if the last dose is at least 6 months prior to Day 1.
* Current therapy with immunosuppressive medications (including steroids), other systemic anti-neoplastic, or investigational agents

a) Prednisone (or equivalent) ≤10 mg/day may be used for non-lymphomatous purposes
* Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within 6 months prior to the first dose of study drugs
* Congestive heart failure, Class III or IV, by the NYHA criteria
* Grade 2 or higher peripheral sensory or motor neuropathy at baseline

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Alabama Research

Birmingham, Alabama, United States

Site Status

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States

Site Status

University of California Davis Medical Center

Sacramento, California, United States

Site Status

Florida Cancer Specialists

Bonita Springs, Florida, United States

Site Status

Florida Cancer Specialists

Bradenton, Florida, United States

Site Status

Florida Cancer Specialists

Cape Coral, Florida, United States

Site Status

Florida Cancer Specialists

Daytona Beach, Florida, United States

Site Status

Florida Cancer Specialists

Fort Myers, Florida, United States

Site Status

Florida Cancer Specialists

Fort Myers, Florida, United States

Site Status

Florida Cancer Specialists

Naples, Florida, United States

Site Status

Florida Cancer Specialists

Port Charlotte, Florida, United States

Site Status

Florida Cancer Specialists

Sarasota, Florida, United States

Site Status

Florida Cancer Specialists

Sarasota, Florida, United States

Site Status

Florida Cancer Specialists

Stuart, Florida, United States

Site Status

Florida Cancer Specialists

Venice, Florida, United States

Site Status

Florida Cancer Specialists

Venice, Florida, United States

Site Status

Florida Cancer Specialists

Vero Beach, Florida, United States

Site Status

Florida Cancer Specialists

Wellington, Florida, United States

Site Status

Florida Cancer Specialists

West Palm Beach, Florida, United States

Site Status

MidAmerica Division, Inc. c/o Menorah Medical Center

Overland Park, Kansas, United States

Site Status

University of Maryland, Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States

Site Status

Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status

Henry Ford Hospital

Detroit, Michigan, United States

Site Status

IP ADDRESS: Brigitte Harris Cancer Pavilion (BHCP)

Detroit, Michigan, United States

Site Status

Karmanos Cancer Institute Weisberg Cancer Treatment Center

Farmington Hills, Michigan, United States

Site Status

Henry Ford Medical Center - Columbus

Novi, Michigan, United States

Site Status

Siteman Cancer Center - St. Peters

City of Saint Peters, Missouri, United States

Site Status

Siteman Cancer Center - West County

Creve Coeur, Missouri, United States

Site Status

MidAmerica Division, Inc. c/o Centerpoint Medical Center

Independence, Missouri, United States

Site Status

MidAmerica Division, Inc., c/o Research Medical Center

Kansas City, Missouri, United States

Site Status

Barnes Jewish-Hospital

St Louis, Missouri, United States

Site Status

Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, United States

Site Status

Siteman Cancer Center - South County

St Louis, Missouri, United States

Site Status